跳至主要内容
临床试验/NCT05448144
NCT05448144招募中不适用

Alterations of Gut Microbiota and Metabolites in Asian Patients With Alcohol-associated Liver Disease

Wuhan Union Hospital, China1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2022年6月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
200
试验地点
1
主要终点
The alterations of gut microbiota in different groups

研究概览

简要总结

Alcohol-associated liver disease is one of the most prevalent liver diseases worldwide, and the leading cause of liver transplantation in the U.S. Alcohol-related liver disease is associated with changes in the intestinal microbiota and metabolites.

详细描述

Backgrounds:

Alcohol-associated liver disease (ALD) is a common disease caused by alcohol use disorder (AUD), ranging from asymptomatic liver steatosis to alcohol-associated hepatitis (AH), alcoholic cirrhosis and potentially, hepatocellular carcinoma (HCC). ALD is the most common reason for liver transplantation in the United States. Globally, about 2 million people die from liver disease each year and up to 50% of the death with cirrhosis can be attributed to alcohol consumption. In Europe, it has been estimated that 60%-80% of liver-related deaths can be attributed to alcohol consumption. Currently, the pathogenetic mechanisms have not been fully elucidated, but they might be related to oxidative stress, acetaldehyde-induced toxicity, cytokine and chemokine-induced inflammation. There is no effective therapeutic method for ALD till now except for liver transplantation. Recent studies have reported that gut microbiota has an intimate relationship with ALD, which provides broader insights and opportunities for understanding and treating this disease.

Aims:

We aim to map the alterations of gut microbiota and metabolites in patients with different levels of ALD, and to investigate the effects and mechanisms of key strains and their metabolites on the development of ALD, providing a theoretical basis and potential targets for its treatment.

Methods:

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • The group of ALD:
  • aged >18 years;
  • patients who meet the diagnostic criteria of ALD in Chinese Guideline for the Prevention and Management of Alcoholic Liver Disease (2018 Update);
  • history of chronic heavy alcohol consumption;
  • with relatively complete clinical data and good compliance.
  • The group of purely drinking:
  • aged >18 years;
  • history of chronic alcohol consumption;
  • no evidence of fatty liver, hepatitis or liver injury.
  • The group of healthy control:
  • aged >18 years;
  • without history of alcohol consumption;
  • no evidence of fatty liver, hepatitis or liver injury.

排除标准

  • with hepatocellular carcinoma or hepatic metastases;
  • combined with infectious liver diseases, such as hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D virus, hepatitis E virus and human immunodeficiency virus (HIV);
  • combined with non-infectious liver diseases, such as non-alcoholic fatty liver disease, drug-induced hepatitis, autoimmune liver disease, Immunoglobulin G subclass 4-related liver disease, Wilson's disease, alpha 1-antitrypsin deficiency, Budd-Chiari syndrome, and other congenital liver diseases;
  • combined with severe organic lesions of other organs;
  • pregnant and lactating women.

结局指标

主要结局

The alterations of gut microbiota in different groups

时间窗: When subjects are enrolled

The alterations will be detected by genome sequencing

The alterations of gut metabolites in different group

时间窗: When subjects are enrolled

The alterations will be detected by metabolomics

次要结局

未报告次要终点

研究者

发起方
Wuhan Union Hospital, China
申办方类型
Other
责任方
Principal Investigator
主要研究者

Huikuan Chu, MD

Associate chief physician

Wuhan Union Hospital, China

研究点 (1)

Loading locations...

相似试验